SIGLEC15 and neoplasm: TCSCs overexpress a variety of immunosuppressive molecules such as PD-L1, SIGLEC15, and others to evade immune attack, so blocking suppressive immune checkpoints will reactivate or restore the killing function of anti-tumor-specific immune cells.